| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
Announced positive topline data from Phase 1 driving simulation trial of GlyphAlloTM, showing that GlyphAllo did not impair next-morning driving performance compared to placebo |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition
Enrollment in Phase 2b BUOY-1 trial of GlyphAlloTM in major depressive disorder (MDD) is on track with topline data expected in 1H 2027 |
| 08 Jun 2026 |
8-K: Results of Operations and Financial Condition
New data from Phase 1 trial of GlyphAgoTM build upon previously reported topline data and further demonstrate GlyphAgoTM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or e... |
| 04 May 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States that is fixed by or i... |
Loading...